Health
bioMérieux: BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization – Business Wire
Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary
MARCY LÉTOILE, France–(BUSINESS WIRE)–Regulatory News:
bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause…
-
Business23 hours agoWhy Amotiv, Breville, Life360, and Woodside shares are tumbling today
-
Noosa News22 hours agoNicole Kidman Is Back in Wellness Guru Mode: ‘Nine Perfect Strangers’ Season Two Will Hit Your Streaming Queue in May
-
Noosa News20 hours agoCloud Control celebrate 15 years of debut album Bliss Release with reunion tour
-
General17 hours agoUK’s AUKUS inquiry is unlikely to suggest the government pull out, expert says